Neuroimaging Biomarkers for Psychosis

Current Behavioral Neuroscience Reports

Volumn 2, Issue 2, 2015, Pages 102-111

  Hager, Brandon M ^a   Keshavan, Matcheri S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

fMRI; MRS; Neuroimaging biomarkers; PET; Psychosis MRI

Indexed keywords

EID: 85090090300     PISSN: None     EISSN: 21962979     Source Type: Journal    
DOI: 10.1007/s40473-015-0035-4     Document Type: Review

References (72)

1. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95. DOI: 10.1067/mcp.2001.113989
2. Prata D, Mechelli A, Kapur S. Clinically meaningful biomarkers for psychosis: a systematic and quantitative review. Neurosci Biobehav Rev. 2014;45:134–41. A systematic look at the value of biomarkers for clinical psychiatry. The results are sobering, with only one biomarker possibly meeting the stringent criteria for a clinically useful biomarker. DOI: 10.1016/j.neubiorev.2014.05.010
3. Keshavan MS, Tandon R, Boutros NN, Nasrallah HA. Schizophrenia, "just the facts": what we know in 2008 Part 3: neurobiology. Schizophr Res. 2008;106(2–3):89–107. DOI: 10.1016/j.schres.2008.07.020
4. Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions. 2008. Available from: http://www.cochrane-handbook.org/.
5. Nakagawa S, Cuthill IC. Effect size, confidence interval and statistical significance: a practical guide for biologists. Biol Rev Camb Philos Soc. 2007;82(4):591–605. DOI: 10.1111/j.1469-185X.2007.00027.x
6. Pantelis C, Yücel M, Wood SJ, et al. Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. Schizophr Bull. 2005;31(3):672–96. DOI: 10.1093/schbul/sbi034
7. Shepherd A, Laurens K, Matheson S, Carr V, Green M. Systematic meta-review and quality assessment of the structural brain alterations in schizophrenia. Neurosci Biobehav Rev. 2012;36:1342–56. An exhaustive meta-review synthesizing the available information from systematic reviews of structural alterations in both chronic and first-episode schizophrenia. DOI: 10.1016/j.neubiorev.2011.12.015
8. Bora E, Fornito A, Radua J, Walterfang M, Seal M, Wood SJ, et al. Neuroanatomical abnormalities in schizophrenia: a multimodal voxelwise meta-analysis and meta-regression analysis. Schizophr Res. 2011;127(1–3):46–57. DOI: 10.1016/j.schres.2010.12.020
9. Shea BJ, Bouter LM, Peterson J, et al. External validation of a measurement tool to assess systematic reviews (AMSTAR). PLoS ONE. 2007;2(12):e1350. DOI: 10.1371/journal.pone.0001350
10. Shea BJ, Hamel C, Wells GA, et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol. 2009;62(10):1013–20. DOI: 10.1016/j.jclinepi.2008.10.009
11. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60. DOI: 10.1136/bmj.327.7414.557
12. Cohen J. Statistical power analysis for the behavioural sciences. 2nd ed. Hillsdale: Lawrence Erlbaum Associates; 1988.
13. Hedges L, Holkin I. Statistical methods for meta-analysis. New York: Academic Press; 1985.
14. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34. DOI: 10.1136/bmj.315.7109.629
15. Haijma SV, Van Haren N, Cahn W, Koolschijn PC, Hulshoff Pol HE, Kahn RS. Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects. Schizophr Bull. 2013;39(5):1129–38. DOI: 10.1093/schbul/sbs118
16. Adriano F, Spoletini I, Caltagirone C, Spalletta G. Updated meta-analyses reveal thalamus volume reduction in patients with first-episode and chronic schizophrenia. Schizophr Res. 2010;123(1):1–14. DOI: 10.1016/j.schres.2010.07.007
17. Adriano F, Caltagirone C, Spalletta G. Hippocampal volume reduction in first-episode and chronic schizophrenia: a review and meta-analysis. Neurosci: Rev J Bringing Neurobiol Neurol Psychiatry. 2012;18(2):180–200.
18. Vita A, De Peri L, Silenzi C, Dieci M. Brain morphology in first-episode schizophrenia: a meta-analysis of quantitative magnetic resonance imaging studies. Schizophr Res. 2006;82(1):75–88. DOI: 10.1016/j.schres.2005.11.004
19. De Peri L, Crescini A, Deste G, Fusar-poli P, Sacchetti E, Vita A. Brain structural abnormalities at the onset of schizophrenia and bipolar disorder: a meta-analysis of controlled magnetic resonance imaging studies. Curr Pharm Des. 2012;18(4):486–94. DOI: 10.2174/138161212799316253
20. Boos HB, Aleman A, Cahn W, Hulshoff Pol H, Kahn RS. Brain volumes in relatives of patients with schizophrenia: a meta-analysis. Arch Gen Psychiatry. 2007;64(3):297–304. DOI: 10.1001/archpsyc.64.3.297
21. Arnone D, Cavanagh J, Gerber D, Lawrie S, Ebmeier K, Mcintosh A. Magnetic resonance imaging studies in bipolar disorder and schizophrenia: meta-analysis. Br J Psychiatry. 2009;195:194–201. DOI: 10.1192/bjp.bp.108.059717
22. Kempton MJ, Geddes JR, Ettinger U, Williams SC, Grasby PM. Meta-analysis, database, and meta-regression of 98 structural imaging studies in bipolar disorder. Arch Gen Psychiatry. 2008;65(9):1017–32. DOI: 10.1001/archpsyc.65.9.1017
23. Arnone D, Mcintosh AM, Tan GM, Ebmeier KP. Meta-analysis of magnetic resonance imaging studies of the corpus callosum in schizophrenia. Schizophr Res. 2008;101(1–3):124–32. DOI: 10.1016/j.schres.2008.01.005
24. Ivleva EI, Bidesi AS, Keshavan MS, et al. Gray matter volume as an intermediate phenotype for psychosis: Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP). Am J Psychiatry. 2013;170(11):1285–96. DOI: 10.1176/appi.ajp.2013.13010126
25. Vita A, Peri L, Deste G, Sacchetti E. Progressive loss of cortical gray matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studies. Transl Psychiatry. 2012;2:E190. DOI: 10.1038/tp.2012.116
26. Olabi B, Ellison-Wright I, McIntosh AM, Wood SJ, Bullmore E, Lawrie SM. Are there progressive brain changes in schizophrenia? A meta-analysis of structural magnetic resonance imaging studies. Biol Psychiatry. 2011;70:88–96. DOI: 10.1016/j.biopsych.2011.01.032
27. Fusar-Poli P, Smieskova R, Kempton M, Ho B, Andreasen N, Borgwardt S. Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. Neurosci Biobehav Rev. 2013;37:1680–91. DOI: 10.1016/j.neubiorev.2013.06.001
28. Kempton MJ, Stahl D, Williams SCR, DeLisi LE. Progressive lateral ventricular enlargement in schizophrenia: a meta-analysis of longitudinal MRI studies. Schizophr Res. 2010;120(1–3):54–62. DOI: 10.1016/j.schres.2010.03.036
29. Fusar-Poli P, Meyer-Lindenberg A. Striatal presynaptic dopamine in schizophrenia, part ii: meta-analysis of [18 F/11C]-DOPA PET studies. Schizophr Bull. 2012;33–42.
30. Howes O, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry. 2012;69(8):776–86. DOI: 10.1001/archgenpsychiatry.2012.169
31. Kraguljac NV, Reid M, White D, et al. Neurometabolites in schizophrenia and bipolar disorder—a systematic review and meta-analysis. Psychiatry Res. 2012;203(2–3):111–25. DOI: 10.1016/j.pscychresns.2012.02.003
32. Brugger S, Davis J, Leucht S, Stone J. Proton magnetic resonance spectroscopy and illness stage in schizophrenia—a systematic review and meta-analysis. Biol Psychiatry. 2011;69:495–503. DOI: 10.1016/j.biopsych.2010.10.004
33. Marsman A, Heuvel M, Klomp D, Kahn R, Luijten P, Pol H. Glutamate in schizophrenia: a focused review and meta-analysis of 1H-MRS studies. Schizophr Bull. 2013;39(1):120–9. DOI: 10.1093/schbul/sbr069
34. Mondino M, Brunelin J, Saoud M. N-acetyl-aspartate level is decreased in the prefrontal cortex in subjects at-risk for schizophrenia. Front Psychiatry. 2013;4:99. DOI: 10.3389/fpsyt.2013.00099
35. Patel S, Mahon K, Wellington R, Zhang J, Chaplin W, Szeszko PR. A meta-analysis of diffusion tensor imaging studies of the corpus callosum in schizophrenia. Schizophr Res. 2011;129(2–3):149–55. DOI: 10.1016/j.schres.2011.03.014
36. Ellison-wright I, Bullmore E. Meta-analysis of diffusion tensor imaging studies in schizophrenia. Schizophr Res. 2009;108(1–3):3–10. DOI: 10.1016/j.schres.2008.11.021
37. Kuswanto CN, Teh I, Lee TS, Sim K. Diffusion tensor imaging findings of white matter changes in first episode schizophrenia: a systematic review. Clin Psychopharmacol Neurosci. 2012;10(1):13–24. DOI: 10.9758/cpn.2012.10.1.13
38. Minzenberg MJ, Laird AR, Thelen S, Carter CS, Glahn DC. Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia. Arch Gen Psychiatry. 2009;66(8):811–22. DOI: 10.1001/archgenpsychiatry.2009.91
39. Macdonald AW, Thermenos HW, Barch DM, Seidman LJ. Imaging genetic liability to schizophrenia: systematic review of FMRI studies of patients' nonpsychotic relatives. Schizophr Bull. 2009;35(6):1142–62. DOI: 10.1093/schbul/sbn053
40. Smieskova R, Marmy J, Schmidt A, et al. Do subjects at clinical high risk for psychosis differ from those with a genetic high risk?—a systematic review of structural and functional brain abnormalities. Curr Med Chem. 2013;20(3):467–81.
41. Taylor SF, Kang J, Brege IS, Tso IF, Hosanagar A, Johnson TD. Meta-analysis of functional neuroimaging studies of emotion perception and experience in schizophrenia. Biol Psychiatry. 2012;71(2):136–45. DOI: 10.1016/j.biopsych.2011.09.007
42. Fusar-poli P. Voxel-wise meta-analysis of fMRI studies in patients at clinical high risk for psychosis. J Psychiatry Neurosci. 2012;37(2):106–12. DOI: 10.1503/jpn.110021
43. Cooper D, Barker V, Radua J, Fusar-poli P, Lawrie SM. Multimodal voxel-based meta-analysis of structural and functional magnetic resonance imaging studies in those at elevated genetic risk of developing schizophrenia. Psychiatry Res. 2014;221(1):69–77. DOI: 10.1016/j.pscychresns.2013.07.008
44. Radua J, Borgwardt S, Crescini A, et al. Multimodal meta-analysis of structural and functional brain changes in first episode psychosis and the effects of antipsychotic medication. Neurosci Biobehav Rev. 2012;36(10):2325–33. DOI: 10.1016/j.neubiorev.2012.07.012
45. Jardri R, Pouchet A, Pins D, Thomas P. Cortical activations during auditory verbal hallucinations in schizophrenia: a coordinate-based meta-analysis. Am J Psychiatry. 2011;168(1):73–81. DOI: 10.1176/appi.ajp.2010.09101522
46. Fusar-poli P, Broome MR, Woolley JB, et al. Altered brain function directly related to structural abnormalities in people at ultra high risk of psychosis: longitudinal VBM-fMRI study. J Psychiatr Res. 2011;45(2):190–8. DOI: 10.1016/j.jpsychires.2010.05.012
47. Tamminga CA, Pearlson G, Keshavan M, Sweeney J, Clementz B, Thaker G. Bipolar and schizophrenia network for intermediate phenotypes: outcomes across the psychosis continuum. Schizophr Bull. 2014;40 Suppl 2:S131–7. DOI: 10.1093/schbul/sbt179
48. Hyman SE. Can neuroscience be integrated into the DSM-V? Nat Rev Neurosci. 2007;8(9):725–32. DOI: 10.1038/nrn2218
49. Velakoulis D, Wood SJ, Wong MT, McGorry PD, Yung A, Phillips L, et al. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Arch Gen Psychiatry. 2006;63(2):139–49. DOI: 10.1001/archpsyc.63.2.139
50. Thermenos HW, Keshavan MS, Juelich RJ, et al. A review of neuroimaging studies of young relatives of individuals with schizophrenia: a developmental perspective from schizotaxia to schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2013;162B(7):604–35. DOI: 10.1002/ajmg.b.32170
51. Cannon TD, Chung Y, He G, et al. Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk. Biol Psychiatry. 2014. doi:10.1016/j.biopsych.2014.05.023.
52. Mattai AA, Weisinger B, Greenstein D, et al. Normalization of cortical gray matter deficits in nonpsychotic siblings of patients with childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry. 2011;50(7):697–704. DOI: 10.1016/j.jaac.2011.03.016
53. Mcgorry P, Keshavan M, Goldstone S, et al. Biomarkers and clinical staging in psychiatry. World Psychiatry. 2014;13(3):211–23. A proposal of a new clinical staging model for severe mental disorders and the ways in which biomarkers could be integrated into such a framework. DOI: 10.1002/wps.20144
54. Fusar-poli P, Howes OD, Allen P, et al. Abnormal frontostriatal interactions in people with prodromal signs of psychosis: a multimodal imaging study. Arch Gen Psychiatry. 2010;67(7):683–91. DOI: 10.1001/archgenpsychiatry.2010.77
55. Gottesman II, Gould TD. The endophenotype concept in psychiatry: ety-mology and strategic intentions. Am J Psychiatry. 2003;160:636–45. DOI: 10.1176/appi.ajp.160.4.636
56. Prasad KM, Keshavan MS. Structural cerebral variations as useful endophenotypes in schizophrenia: do they help construct "extended endophenotypes"? Schizophr Bull. 2008;34(4):774–90. DOI: 10.1093/schbul/sbn017
57. Thompson PM, Stein JL, Medland SE, et al. The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging Behav. 2014;8(2):153–82. A review of the current progress of the ENIGMA Consortium, a collaborative network of researchers working together on a range of large-scale studies that integrate neuroimaging and genetic data from 70 institutions worldwide.
58. DC V, Smith SM, Barch DM, et al. The WU-Minn Human Connectome Project: an overview. Neuroimage. 2013;80:62–79. A review of the systematic effort to map macroscopic human brain circuits, and the progress made in refining the methods for data acquisition and analysis. DOI: 10.1016/j.neuroimage.2013.05.041
59. Cocchi L, Harding IH, Lord A, Pantelis C, Yucel M, Zalesky A. Disruption of structure-function coupling in the schizophrenia connectome. Neuroimage Clin. 2014;4:779–87. A study with results supporting the core nature of fronto-striatal, fronto-thalamic, and fronto-temporal abnormalities in the schizophrenia connectome. DOI: 10.1016/j.nicl.2014.05.004
60. Keshavan MS, Clementz BA, Pearlson GD, Sweeney JA, Tamminga CA. Reimagining psychoses: an agnostic approach to diagnosis. Schizophr Res. 2013;146(1–3):10–6. A review of the evolution, current status and the constraints posed by traditional symptom-based diagnostic approaches in psychiatry, and a proposal to develop a biomarker-based approach. DOI: 10.1016/j.schres.2013.02.022
61. Jack CR, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain. 2009;132(Pt 5):1355–65. An article attempting to utilize neuroimaging methods to identify biomarkers for Alzheimer’s disease. DOI: 10.1093/brain/awp062
62. Kempton MJ, Mcguire P. How can neuroimaging facilitate the diagnosis and stratification of patients with psychosis?. Eur Neuropsychopharmacol. 2014. An article reviewing the current progress of utilizing neuroimaging methodologies to identify biomarkers for psychosis.
63. Orrù G, Pettersson-yeo W, Marquand AF, Sartori G, Mechelli A. Using support vector machine to identify imaging biomarkers of neurological and psychiatric disease: a critical review. Neurosci Biobehav Rev. 2012;36(4):1140–52. The article provides a useful overview of the applications of machine based learning to imaging biomarkers in neuropsychiatry. DOI: 10.1016/j.neubiorev.2012.01.004
64. Koutsouleris N, Meisenzahl EM, Davatzikos C, et al. Use of neuroanatomical pattern classification to identify subjects in at-risk mental states of psychosis and predict disease transition. Arch Gen Psychiatry. 2009;66(7):700–12. DOI: 10.1001/archgenpsychiatry.2009.62
65. BN V, Bossong MG, Boellaard R, et al. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry. 2008;64(9):820–2. DOI: 10.1016/j.biopsych.2008.04.025
66. Pasternak O, Westin CF, Bouix S, et al. Excessive extracellular volume reveals a neurodegenerative pattern in schizophrenia onset. J Neurosci. 2012;32(48):17365–72. DOI: 10.1523/JNEUROSCI.2904-12.2012
67. Wood SJ, Berger GE, Wellard RM, et al. Medial temporal lobe glutathione concentration in first episode psychosis: a 1H-MRS investigation. Neurobiol Dis. 2009;33(3):354–7. DOI: 10.1016/j.nbd.2008.11.018
68. Kellendonk C, Simpson EH, Kandel ER. Modeling cognitive endophenotypes of schizophrenia in mice. Trends Neurosci. 2009;32(6):347–58. DOI: 10.1016/j.tins.2009.02.003
69. Smucny J, Wylie KP, Tregellas JR. Functional magnetic resonance imaging of intrinsic brain networks for translational drug discovery. Trends Pharmacol Sci. 2014;35(8):397–403. This article shows how intrinsic networks may show similar abnormalities in human diseases and animal models of these diseases, supporting their use as biomarkers in drug development in schizophrenia. DOI: 10.1016/j.tips.2014.05.001
70. Abramson RG, Burton KR, Yu JP, et al. Methods and challenges in quantitative imaging biomarker development. Acad Radiol. 2015;22(1):25–32. A discussion of the motivations for advancing quantitative imaging as a tool for biomarker research and development. DOI: 10.1016/j.acra.2014.09.001
71. Barnes DE, Cenzer IS, Yaffe K, Ritchie CS, Lee SJ. A point-based tool to predict conversion from mild cognitive impairment to probable Alzheimer's disease. Alzheimers Dement. 2014;10(6):646–55. Development of a novel point-based risk score combining functional dependence, cerebral MRI measures, and neuropsychological test scores which provided good accuracy for prediction of conversion from amnestic mild cognitive impairment to Alzheimer’s disease. DOI: 10.1016/j.jalz.2013.12.014
72. Cannon TD, Chung Y, He G, et al. Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk. Biol Psychiatry. 2015;77(2):147–57. DOI: 10.1016/j.biopsych.2014.05.023